The FDA’s Oncologic Drugs Advisory Committee regards the STARGLO international clinical trial of glofitamab plus gemcitabine and oxaliplatin for DLBCL to be inapplicable to patient populations in the United States.
Interferon improved myelofibrosis-free survival in adolescent and young adult patients with polycythemia vera.
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
The safety results from this phase 2 trial were also consistent with those observed in other studies.
The approval is based on the DREAMM-7 and DREAMM-8 trials, in which belantamab mafodotin showed favorable survival benefit.
A short duration of covalent BTKi therapy and early disease progression were associated with low incidence of BTK mutations.
Podcasts
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Video Insights
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
Study finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
Yesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology